
N4 Pharma PLC
LSE:N4P

Intrinsic Value
The intrinsic value of one
N4P
stock under the Base Case scenario is
0.01
GBX.
Compared to the current market price of 0.45 GBX,
N4 Pharma PLC
is
Overvalued by 98%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
N4 Pharma PLC
Loading...
Fundamental Analysis


Revenue & Expenses Breakdown
N4 Pharma PLC
Balance Sheet Decomposition
N4 Pharma PLC
Current Assets | 775.8k |
Cash & Short-Term Investments | 626k |
Receivables | 149.8k |
Free Cash Flow Analysis
N4 Pharma PLC
GBP | |
Free Cash Flow | GBP |
Earnings Waterfall
N4 Pharma PLC
Revenue
|
7.3k
GBP
|
Operating Expenses
|
-1.2m
GBP
|
Operating Income
|
-1.2m
GBP
|
Other Expenses
|
162.5k
GBP
|
Net Income
|
-1.1m
GBP
|
N4P Profitability Score
Profitability Due Diligence
N4 Pharma PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Score
N4 Pharma PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
N4P Solvency Score
Solvency Due Diligence
N4 Pharma PLC's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Score
N4 Pharma PLC's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
N4P Price Targets Summary
N4 Pharma PLC
Dividends
Current shareholder yield for N4P is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
N4P
stock under the Base Case scenario is
0.01
GBX.
Compared to the current market price of 0.45 GBX,
N4 Pharma PLC
is
Overvalued by 98%.